Premium
Reprogramming cells and their use in regenerative therapy (19.2)
Author(s) -
Chilian William
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.19.2
Subject(s) - progenitor cell , reprogramming , stem cell , mesenchymal stem cell , collateral circulation , medicine , cell therapy , microbiology and biotechnology , biology , cell , genetics
The growth of the coronary collateral circulation has a beneficial effect on the consequences of ischemic heart disease. Despite this importance, strategies to develop coronary collaterals have not been successful. For example, administration of growth factors has not been successful in stimulating the growth of coronary collaterals in patients. Because of these shortcomings, we adopted new strategies to stimulate coronary collateral vessels using genetically reprogrammed cells. We reprogrammed endothelial cells into a progenitor‐like cell that remains committed to a vascular differentiation program and can become either smooth muscle or endothelium (termed induced vascular progenitor cells [iVPCs]). Administration of iVPCs stimulated the growth of collateral vessels in the heart. Other types of stem cells (mesenchymal stem cells, cardiac stem cells) or native endothelial cells did not have the same stimulatory effect on coronary collateral growth. Although the mechanisms by which iVPCs stimulate collateral growth have not been unequivocally defined, these cells incorporate and engraft in growing blood vessels in the heart. Although the benefit of using reprogrammed cells to stimulate vascular growth in the heart in models of vascular disease is not yet defined, the use of certain types of reprogrammed cells may offer a substantial advance in the treatment of ischemic heart disease.